Promising lyme vaccine moves to final testing phase

NCT ID NCT07226882

First seen Nov 12, 2025 · Last updated Jun 13, 2026 · Updated 31 times

Summary

This study tests a new Lyme disease vaccine (VLA15) in about 200 healthy adults aged 18 to 44. Participants receive five shots over two years—four of the vaccine and one of salt water—to see if different timing schedules are safe and produce a strong immune response. The goal is to find the best way to protect people from Lyme disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYME DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • IMA Clinical Research Warren

    Warren Township, New Jersey, 07059, United States

  • Northeast Clinical Trials Group

    Scranton, Pennsylvania, 18510, United States

  • Preferred Primary Care Physicians

    Uniontown, Pennsylvania, 15401, United States

  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)

    Pittsburgh, Pennsylvania, 15236, United States

  • Smith Allergy & Asthma Specialists

    Horseheads, New York, 14845, United States

  • Smith Allergy and Asthma Specialists

    Cortland, New York, 13045, United States

Conditions

The condition(s) this trial relates to.

Lyme disease Lyme Neuroborreliosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.